Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amending IPAB: Lack Of Administrative, Judicial Review Raises Concern

Executive Summary

Stakeholders interested in curtailing the sweeping authority given the Independent Payment Advisory Board by the health reform law are taking a close look at provisions barring administrative or judicial review of the panel's Medicare cost-cutting policies

You may also be interested in...

Key House Medicare Subcommittee Will Have New Leaders; Rep. Stark Loses Election Bid

Rep. Pete Stark, D-Calif., often a critic of the pharmaceutical industry, lost his re-election bid, leaving the top Democratic spot open on the Ways and Means Committee’s Health Subcommittee. Subcommittee Chairman Wally Herger already planned to retire. All members of the Senate HELP and Finance Committees up for re-election won their races.

IPAB Members Will Be Named In Time To Begin Recommendations In 2014, Sebelius Says

The White House has begun discussions with potential board member nominees, HHS secretary tells House Energy and Commerce Health Subcommittee.

Mandatory Part D Drug Rebates Proposed By Deficit Panel Leaders; Stronger IPAB Also On The Table

The co-chairs of the bipartisan National Commission on Fiscal Responsibility and Reform issued a cost-savings proposal for the government, including Medicare, on Nov. 10, but it will need approval by 14 of 18 members before going to the president.

Related Content


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts